← Back to Search

Antibiotic

Daptomycin for Febrile Neutropenia

Phase 3
Waitlist Available
Led By Robert F Betts, MD
Research Sponsored by University of Rochester
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 days
Awards & highlights

Summary

The purpose of this study is to evaluate the benefits and side effects of daptomycin compared to placebo for the treatment of neutropenic fever.

Eligible Conditions
  • Febrile Neutropenia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Afebrile Neutropenic Subjects

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: DaptomycinActive Control1 Intervention
Daptomycin intravenous 8mg/kg once per day 5-10 days.
Group II: Saline PlaceboPlacebo Group1 Intervention
Saline solution

Find a Location

Who is running the clinical trial?

Cubist Pharmaceuticals LLCIndustry Sponsor
88 Previous Clinical Trials
22,650 Total Patients Enrolled
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry Sponsor
88 Previous Clinical Trials
22,650 Total Patients Enrolled
University of RochesterLead Sponsor
859 Previous Clinical Trials
538,669 Total Patients Enrolled
~2 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top